or
forgot password

A Phase 1 Dose Escalation Study of TTI-237 Administered Intravenously Every 3 Weeks in Subjects With Advanced Malignant Solid Tumors


Phase 1
18 Years
N/A
Not Enrolling
Both
Neoplasms

Thank you

Trial Information

A Phase 1 Dose Escalation Study of TTI-237 Administered Intravenously Every 3 Weeks in Subjects With Advanced Malignant Solid Tumors


Inclusion Criteria:



- Documented diagnosis of malignant solid tumor with measurable disease

- Life expectancy of at least 12 weeks

- ECOG performance status of 0, 1, or 2

Exclusion Criteria:

- Recent major surgery, radiation therapy or anti-cancer treatment

- History of any other prior malignancy within the last 5 years

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Primary purpose is to address the safety and tolerability of TTI-237. Patient will be assessed on an ongoing basis during their participation on the trial.

Principal Investigator

Medical Monitor

Investigator Role:

Study Director

Investigator Affiliation:

Wyeth is now a wholly owned subsidiary of Pfizer

Authority:

United States: Food and Drug Administration

Study ID:

3162K1-101

NCT ID:

NCT00195247

Start Date:

May 2005

Completion Date:

Related Keywords:

  • Neoplasms
  • Tumors
  • Advanced malignant solid tumors
  • Neoplasms

Name

Location
Phoenix, Arizona  85012
Fountain Valley, California  92708
Baltimore, Maryland  21287